Market Cap 9.74B
Revenue (ttm) 0.00
Net Income (ttm) -425.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,800,272
Avg Vol 2,142,848
Day's Range N/A - N/A
Shares Out 79.00M
Stochastic %K 99%
Beta 1.15
Analysts Sell
Price Target $130.34

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 357 7000
Address:
One Broadway, 14th Floor, Cambridge, United States
De12
De12 Jun. 26 at 2:30 PM
$NUVB Getting Co Ready For buyout like $NUVL Look at that Volume!!
0 · Reply
De12
De12 Jun. 25 at 6:43 PM
$NUVB Getting this baby ready for Sale! like $NUVL loading the Dip!
0 · Reply
De12
De12 Jun. 25 at 12:03 PM
$NUVB Paying back loan plus 550 Million Cash on Hand, Getting Co Ready for $NUVL type Buyout?
1 · Reply
IN0V8
IN0V8 Jun. 19 at 2:14 AM
$NUVL that 1 was spot on 🎯 https://stocktwits.com/IN0V8/message/655100043
0 · Reply
ClassiTrader
ClassiTrader Jun. 19 at 1:51 AM
$NUVL popped
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 18 at 7:33 AM
$ONC holy hell, zbeigene is still in business? And trading at a 60 p/e? Can’t short this and other certain biotech stocks enough @Shortseller $GSK bought $NUVL for a reason. BeOne? beigene? Be Gone 😂 s
1 · Reply
StreetwiseReports
StreetwiseReports Jun. 17 at 8:16 PM
Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies https://ow.ly/9II950ZcV80 Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider. $NUVL
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 17 at 4:41 PM
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal https://ow.ly/epYB50ZcPIN Analysts downgrade Nuvalent Inc ( $NUVL ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely.
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 17 at 2:29 AM
$TNXP $NUVB $MIST $NUVL God Bless America 🇺🇸 💪 🚀
0 · Reply
BioRich
BioRich Jun. 16 at 9:11 PM
$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so. For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
Latest News on NUVL
Nuvalent Transcript: AGM 2026

Jun 16, 2026, 2:00 PM EDT - 10 days ago

Nuvalent Transcript: AGM 2026


Nuvalent downgraded to Neutral from Buy at Guggenheim

2026-06-10T11:09:10.000Z - 16 days ago

Nuvalent downgraded to Neutral from Buy at Guggenheim


Nuvalent downgraded to Neutral from Buy at UBS

2026-06-10T09:00:10.000Z - 17 days ago

Nuvalent downgraded to Neutral from Buy at UBS


Nuvalent downgraded to Hold from Buy at Truist

2026-06-09T20:41:57.000Z - 17 days ago

Nuvalent downgraded to Hold from Buy at Truist


Nuvalent downgraded to Hold from Buy at TD Cowen

2026-06-09T20:26:51.000Z - 17 days ago

Nuvalent downgraded to Hold from Buy at TD Cowen


Nuvalent rises 39.2%

2026-06-09T16:06:19.000Z - 17 days ago

Nuvalent rises 39.2%


Nuvalent downgraded to Hold from Buy at Canaccord

2026-06-09T15:15:37.000Z - 17 days ago

Nuvalent downgraded to Hold from Buy at Canaccord


Nuvalent downgraded to Neutral from Outperform at Baird

2026-06-09T15:15:23.000Z - 17 days ago

Nuvalent downgraded to Neutral from Outperform at Baird


Nuvalent downgraded to Neutral from Overweight at JPMorgan

2026-06-09T14:45:29.000Z - 17 days ago

Nuvalent downgraded to Neutral from Overweight at JPMorgan


Nuvalent downgraded to Hold from Buy at Stifel

2026-06-09T14:25:28.000Z - 17 days ago

Nuvalent downgraded to Hold from Buy at Stifel

GSK


Nuvalent rises 38.9%

2026-06-09T14:01:29.000Z - 17 days ago

Nuvalent rises 38.9%


Nuvalent downgraded to Neutral from Buy at H.C. Wainwright

2026-06-09T13:17:27.000Z - 17 days ago

Nuvalent downgraded to Neutral from Buy at H.C. Wainwright


London's FTSE 100 falls as GSK slides after Nuvalent deal

Jun 9, 2026, 5:13 AM EDT - 18 days ago

London's FTSE 100 falls as GSK slides after Nuvalent deal

GSK


GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

Jun 9, 2026, 2:29 AM EDT - 18 days ago

GSK to Buy Nuvalent for $10.6 Billion in Oncology Push

GSK


Nuvalent Slides: Corporate presentation

May 27, 2026, 8:00 AM EDT - 4 weeks ago

Nuvalent Slides: Corporate presentation


Nuvalent Earnings release: Q1 2026

May 7, 2026, 6:30 AM EDT - 7 weeks ago

Nuvalent Earnings release: Q1 2026


Nuvalent Quarterly report: Q1 2026

May 7, 2026, 6:30 AM EDT - 7 weeks ago

Nuvalent Quarterly report: Q1 2026


Nuvalent Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Nuvalent Proxy statement: Proxy filing


Nuvalent Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Nuvalent Proxy statement: Proxy filing


Nuvalent Slides: Corporate presentation

Apr 8, 2026, 7:00 AM EDT - 2 months ago

Nuvalent Slides: Corporate presentation


Nuvalent Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 2:20 PM EDT - 3 months ago

Nuvalent Transcript: Leerink Global Healthcare Conference 2026


Nuvalent Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Nuvalent Earnings release: Q4 2025


Nuvalent Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Nuvalent Annual report: Q4 2025


Nuvalent Slides: Corporate presentation

Feb 26, 2026, 7:00 AM EST - 4 months ago

Nuvalent Slides: Corporate presentation


Nuvalent Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:00 PM EST - 5 months ago

Nuvalent Transcript: 44th Annual J.P. Morgan Healthcare Conference


Nuvalent Slides: Company presentation

Jan 12, 2026, 7:00 AM EST - 5 months ago

Nuvalent Slides: Company presentation


Nuvalent Appoints Ron Squarer to Board of Directors

Dec 10, 2025, 4:01 PM EST - 7 months ago

Nuvalent Appoints Ron Squarer to Board of Directors


Nuvalent Announces Pricing of Public Offering of Common Stock

Nov 18, 2025, 11:50 PM EST - 7 months ago

Nuvalent Announces Pricing of Public Offering of Common Stock


Nuvalent Announces Public Offering of Common Stock

Nov 17, 2025, 4:01 PM EST - 7 months ago

Nuvalent Announces Public Offering of Common Stock


Nuvalent Transcript: Study Update

Nov 17, 2025, 8:00 AM EST - 7 months ago

Nuvalent Transcript: Study Update


Nuvalent Press release: Study Update

Nov 17, 2025, 8:00 AM EST - 7 months ago

Nuvalent Press release: Study Update


Nuvalent Slides: Study Update

Nov 17, 2025, 8:00 AM EST - 7 months ago

Nuvalent Slides: Study Update


Nuvalent Slides: Corporate Presentation

Oct 30, 2025, 8:00 AM EDT - 8 months ago

Nuvalent Slides: Corporate Presentation


Nuvalent Quarterly report: Q3 2025

Oct 30, 2025, 6:30 AM EDT - 8 months ago

Nuvalent Quarterly report: Q3 2025


Nuvalent Earnings release: Q3 2025

Oct 30, 2025, 6:30 AM EDT - 8 months ago

Nuvalent Earnings release: Q3 2025


Nuvalent Transcript: UBS Virtual Oncology Day

Oct 1, 2025, 3:30 PM EDT - 9 months ago

Nuvalent Transcript: UBS Virtual Oncology Day


Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Sep 24, 2025, 6:30 AM EDT - 9 months ago

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day


Nuvalent Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:45 AM EDT - 10 months ago

Nuvalent Transcript: Cantor Global Healthcare Conference 2025


Nuvalent Quarterly report: Q2 2025

Aug 7, 2025, 6:30 AM EDT - 11 months ago

Nuvalent Quarterly report: Q2 2025


Nuvalent Earnings release: Q2 2025

Aug 7, 2025, 6:30 AM EDT - 11 months ago

Nuvalent Earnings release: Q2 2025


Nuvalent Transcript: Investor Update

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Nuvalent Transcript: Investor Update


Nuvalent Press release: Investor Update

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Nuvalent Press release: Investor Update


Nuvalent Slides: Investor Update

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Nuvalent Slides: Investor Update


Nuvalent Appoints Christy Oliger to Board of Directors

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Nuvalent Appoints Christy Oliger to Board of Directors


De12
De12 Jun. 26 at 2:30 PM
$NUVB Getting Co Ready For buyout like $NUVL Look at that Volume!!
0 · Reply
De12
De12 Jun. 25 at 6:43 PM
$NUVB Getting this baby ready for Sale! like $NUVL loading the Dip!
0 · Reply
De12
De12 Jun. 25 at 12:03 PM
$NUVB Paying back loan plus 550 Million Cash on Hand, Getting Co Ready for $NUVL type Buyout?
1 · Reply
IN0V8
IN0V8 Jun. 19 at 2:14 AM
$NUVL that 1 was spot on 🎯 https://stocktwits.com/IN0V8/message/655100043
0 · Reply
ClassiTrader
ClassiTrader Jun. 19 at 1:51 AM
$NUVL popped
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 18 at 7:33 AM
$ONC holy hell, zbeigene is still in business? And trading at a 60 p/e? Can’t short this and other certain biotech stocks enough @Shortseller $GSK bought $NUVL for a reason. BeOne? beigene? Be Gone 😂 s
1 · Reply
StreetwiseReports
StreetwiseReports Jun. 17 at 8:16 PM
Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies https://ow.ly/9II950ZcV80 Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider. $NUVL
0 · Reply
StreetwiseReports
StreetwiseReports Jun. 17 at 4:41 PM
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal https://ow.ly/epYB50ZcPIN Analysts downgrade Nuvalent Inc ( $NUVL ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely.
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 17 at 2:29 AM
$TNXP $NUVB $MIST $NUVL God Bless America 🇺🇸 💪 🚀
0 · Reply
BioRich
BioRich Jun. 16 at 9:11 PM
$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so. For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
mikesterz7
mikesterz7 Jun. 14 at 6:11 PM
$GSK $NUVL 🚨🚨🚨🚨 GlaxoSmithKline announced its intention to purchase U.S. biopharmaceutical firm Nuvalent in a deal valued at approximately $10.6 billion. GSK plans to initiate a tender offer for all outstanding Nuvalent shares at $124 each, reflecting a 40% premium over Nuvalent's recent closing price. The acquisition is expected to enhance GSK's oncology pipeline with three lung cancer assets, including therapies currently under FDA review, which could receive U.S. approvals by 2026.
0 · Reply
zerodayrounder
zerodayrounder Jun. 14 at 5:46 PM
$GSK media day presentation re $NUVL acquisition. cc $SPRO Ashleigh Furlong (Bloomberg): You mentioned building the oncology portfolio brick-by-brick. I wonder if that house is built yet, and you are happy with where you are? Luke Miels: ****** We remain active, not just in oncology but also other areas where we have expertise.****** What we are looking to employ is a strategy that combines a commitment to innovation but also strong discipline in terms of creating value for our shareholders. We remain active at looking but, again, we first need to digest this transaction, so I think it is one step at a time at this point. Thanks, Ashleigh. https://www.sec.gov/Archives/edgar/data/1131399/000119312526264048/d142612dex99a5b.htm
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 14 at 1:13 PM
$IDYA analyst consensus revenue estimates versus $NUVL & $ACLX via graph & simple 5-year revenue multiple comparison. ACLX was acquired for an EV of $7.3B & NUVB was $9.4B (rounded). None of the 3 have a FDA approved therapy yet though obviously NUVL & ACLX had active PDUFA dates when acquired. Our simple question...if analysts believe IDYA will meaningfully outsell ACLX and, more or less, generate revenues consistent with NUVL, does this suggest IDYA's risk v reward profile is compelling? Are there any reasons IDYA's valuation as a multiple of analysts estimates won't match the 2 (assuming BLA's are submitted)? This is not investment advice. $XBI $NBI
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 13 at 10:01 PM
This is not investment advice. We have no idea what $RVMD might be worth in a hypothetical acquisition. That being said, $NUVL & $ACLX were acquired for an average of 1.5X analyst 5-year FY28 - 32 revenue estimates, excluding the highest estimate for each year, as detailed on the attachment. The 7 RVMD analysts that provide RVMD FY28 - 32 revenue estimates project RVMD to generate $28.421B in revenues over the same 5-year period. Hence if RVMD analyst estimates were credible AND if RVMD were acquired at the same average 5-year revenue multiple of 1.5X (2 ENORMOUS IFs) then RVMD would exit for $42.63B in EV (consistent with NUVL & ACLX multiples). Using RVMD's 3/31/26 cap table, this would be ~$200 per share. We're curious if investors believe RVMD's profile would merit a peer M&A revenue multiple consistent with NUVL & ACLX? Why or why not (i.e. gross margin profile is different, royalty obligations)? We'd genuinely appreciate feedback. This is not investment advice. $XBI $IBB
0 · Reply
zerodayrounder
zerodayrounder Jun. 13 at 3:00 PM
$GSK CEO Luke Miels was the architect behind the 2022 $SPRO equity investment and license agreement for tebipenem (effectively saving SPRO and tebi). He seemed to like it then! How about now as the CEO, with FDA approval any time? Now he LOVES oncology and pivoting GSK portfolio back into cancer drugs with $10.6 billion acquisition of Cambridge MA biotech Nuvalent $NUVL. Perhaps they will go fishing in those "dirty waters" of the Charles River again ..... I'm not an expert but AI tells me Immunitas single cell genomics platform and IMT-009 works well in combination with GSK current oncology franchise, particularly jemperli. So Mr Miels can (1) achieve the completion of his Tebi vision and (2) roll his SPRO shares into Immunitas to gain a toehold ... get a front row look at the science, off-load some R&D onto Immunitas balance sheet AND maybe acquire the rest at a later date. No capital gains on its SPRO investment AND get shot on goal with new oncology science project.
1 · Reply
De12
De12 Jun. 12 at 10:27 AM
$NUVB Stan Druckenmiller purchased over 4.5 million Shares!! $NUVB going to be the next $NUVL
1 · Reply
anachartanalyst
anachartanalyst Jun. 10 at 8:01 PM
$NUVL https://anachart.com/wp-content/uploads/2026/06/1781121702_soc-img.jpg
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 10 at 6:47 PM
$NUVB this is a buying opportunity all. $NUVL is getting bought by $GSK which is good news for Nuvation. David Hung will run circles around GSK’s people 🌪️ Buying the dip 📊
0 · Reply
IN0V8
IN0V8 Jun. 10 at 12:40 PM
$NUVL https://www.barchart.com/story/news/2388163/nuvalent-stock-hits-all-time-high-following-gsk-s-buyout-offer
0 · Reply
John1463
John1463 Jun. 10 at 11:24 AM
$NUVL: Nuvalent stock is beginning to experience strong uplift due to their agreement to be acquired by GSK, valuing it at $124 per share. It's most recent volume was at 51.6 million shares compared to average 1.48 million shares for the past three months. GSK wants to acquire it due to their immense success in clinical trials. Analysts believe their drug therapies can reach peak annual sales of $4 billion when they are currently valued at 9.74 billion. The stock is well-poised to run up some more. $PDC: Perpetuals Ltd stock, which specializes in blockchain-based products and solutions has shown strong recent bullish momentum. Total revenue has also grown dramatically by 146% YoY recently. The 10-day EMA stands very close to the recent closing price, which means the stock is almost ready to run. The RSI still remains neutral even amidst growing volume and bullish interest.
0 · Reply
LewisDaKat
LewisDaKat Jun. 10 at 10:30 AM
$NUVL Neutral Recommendation Issued On NUVL By UBS https://marketwirenews.com/stock/nuvl/news/neutral-recommendation-issued-on-nuvl-by-ubs-6827836707245181.html?utm_source=stocktwits
0 · Reply
Hognose
Hognose Jun. 10 at 10:18 AM
$RYTM premium buyout target. $NUVL was taken now RYTM eventually. $XBI no interest raise and xbi acquisitions will still happen.
0 · Reply